IGM and Sanofi collaboration will pivot to immunology and inflammation
The deal will now see IGM doubling down on IgM antibody development for immunology and inflammation targets.
The deal will now see IGM doubling down on IgM antibody development for immunology and inflammation targets.
The move expedites and enhances research, development and quality-control works linked to advanced therapies.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Bayer and Google Cloud to develop AI solutions for radiologists
Q&A: BARDA wants to back tech that can combat multiple infections, says director
Can pharma overcome generative AI’s bias problem?
NVIDIA doubles down on AI in healthcare with drug discovery deals